Cardiovascular Research · 2018 · 124 citations · 35 references
MedicineCardiologyPharmacologyDrug DeliveryInflammationMolecular PharmacologyAnti-inflammatory PharmacologyCardiac PharmacotherapyInflammation PharmacologyInflammatory MediatorsMacrophage PharmacologyNanomedicineMacrophage PolarizationMonocyte PolarizationMyocardial Infarction ModelsMyocardial Ischemia-reperfusion InjuryMyocardial RepairPeroxisome Proliferator-activated Receptor Gamma AgonismPeroxisome Proliferator-activated Receptor Gamma RegulationPeroxisome Proliferator-activated Receptor Signaling
Aims: Monocyte-mediated inflammation is a major mechanism underlying myocardial ischaemia-reperfusion (IR) injury and the healing process after acute myocardial infarction (AMI). However, no definitive anti-inflammatory therapies have been developed for clinical use. Pioglitazone, a peroxisome proliferator-activated receptor-gamma (PPARγ) agonist, has unique anti-inflammatory effects on monocytes/macrophages. Here, we tested the hypothesis that nanoparticle (NP)-mediated targeting of pioglitazone to monocytes/macrophages ameliorates IR injury and cardiac remodelling in preclinical animal models. Methods and results: We formulated poly (lactic acid/glycolic acid) NPs containing pioglitazone (pioglitazone-NPs). In a mouse IR model, these NPs were delivered predominantly to circulating monocytes and macrophages in the IR heart. Intravenous treatment with pioglitazone-NPs at the time of reperfusion attenuated IR injury. This effect was abrogated by pre-treatment with the PPARγ antagonist GW9662. In contrast, treatment with a pioglitazone solution had no therapeutic effects on IR injury. Pioglitazone-NPs inhibited Ly6Chigh inflammatory monocyte recruitment as well as inflammatory gene expression in the IR hearts. In a mouse myocardial infarction model, intravenous treatment with pioglitazone-NPs for three consecutive days, starting 6 h after left anterior descending artery ligation, attenuated cardiac remodelling by reducing macrophage recruitment and polarizing macrophages towards the pro-healing M2 phenotype. Furthermore, pioglitazone-NPs significantly decreased mortality after MI. Finally, in a conscious porcine model of myocardial IR, pioglitazone-NPs induced cardioprotection from reperfused infarction, thus providing pre-clinical proof of concept. Conclusion: NP-mediated targeting of pioglitazone to inflammatory monocytes protected the heart from IR injury and cardiac remodelling by antagonizing monocyte/macrophage-mediated acute inflammation and promoting cardiac healing after AMI.
35
Heart Disease and Stroke Statistics—2016 Update
Dariush Mozaffarian, Emelia J. Benjamin, Alan S. Go et al. · Circulation · 2015 · 6.6K citations
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Mercedes Ricote, Andrew C. Li, Timothy M. Willson et al. · Nature · 1998 · 3.5K citations
Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites
Filip K. Świrski, Matthias Nahrendorf, Martin Etzrodt et al. · Science · 2009 · 2.2K citations · Full text
Distinct Roles of Autophagy in the Heart During Ischemia and Reperfusion
Yutaka Matsui, Hiromitsu Takagi, Xueping Qu et al. · Circulation Research · 2007 · 1.5K citations